Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 110

1.

Current trends in outwitting resistance development in Candida infections through photodynamic and short peptide therapies: a strategic-shift from conventional antifungal agents.

Louis B, Waikhom SD, Atadja PW.

Expert Rev Anti Infect Ther. 2016 Mar;14(3):345-52. doi: 10.1586/14787210.2016.1147953.

PMID:
26822688
2.

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y, Balbin OA, Barbe S, Cai H, Casey F, Chatterjee S, Chiang DY, Chuai S, Cogan SM, Collins SD, Dammassa E, Ebel N, Embry M, Green J, Kauffmann A, Kowal C, Leary RJ, Lehar J, Liang Y, Loo A, Lorenzana E, Robert McDonald E 3rd, McLaughlin ME, Merkin J, Meyer R, Naylor TL, Patawaran M, Reddy A, Röelli C, Ruddy DA, Salangsang F, Santacroce F, Singh AP, Tang Y, Tinetto W, Tobler S, Velazquez R, Venkatesan K, Von Arx F, Wang HQ, Wang Z, Wiesmann M, Wyss D, Xu F, Bitter H, Atadja P, Lees E, Hofmann F, Li E, Keen N, Cozens R, Jensen MR, Pryer NK, Williams JA, Sellers WR.

Nat Med. 2015 Nov;21(11):1318-25. doi: 10.1038/nm.3954. Epub 2015 Oct 19.

PMID:
26479923
3.

Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53.

Fei Q, Shang K, Zhang J, Chuai S, Kong D, Zhou T, Fu S, Liang Y, Li C, Chen Z, Zhao Y, Yu Z, Huang Z, Hu M, Ying H, Chen Z, Zhang Y, Xing F, Zhu J, Xu H, Zhao K, Lu C, Atadja P, Xiao ZX, Li E, Shou J.

Nat Commun. 2015 Oct 16;6:8651. doi: 10.1038/ncomms9651.

PMID:
26471002
4.

SETDB1 modulates PRC2 activity at developmental genes independently of H3K9 trimethylation in mouse ES cells.

Fei Q, Yang X, Jiang H, Wang Q, Yu Y, Yu Y, Yi W, Zhou S, Chen T, Lu C, Atadja P, Liu XS, Li E, Zhang Y, Shou J.

Genome Res. 2015 Sep;25(9):1325-35. doi: 10.1101/gr.177576.114. Epub 2015 Jul 9.

5.

A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3).

Kaniskan HÜ, Szewczyk MM, Yu Z, Eram MS, Yang X, Schmidt K, Luo X, Dai M, He F, Zang I, Lin Y, Kennedy S, Li F, Dobrovetsky E, Dong A, Smil D, Min SJ, Landon M, Lin-Jones J, Huang XP, Roth BL, Schapira M, Atadja P, Barsyte-Lovejoy D, Arrowsmith CH, Brown PJ, Zhao K, Jin J, Vedadi M.

Angew Chem Int Ed Engl. 2015 Apr 20;54(17):5166-70. doi: 10.1002/anie.201412154. Epub 2015 Feb 27.

6.

Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.

Salmon JM, Bots M, Vidacs E, Stanley KL, Atadja P, Zuber J, Johnstone RW.

Clin Epigenetics. 2015 Jan 22;7(1):2. doi: 10.1186/s13148-014-0034-4. eCollection 2015.

7.

Absolute quantification of histone PTM marks by MRM-based LC-MS/MS.

Gao J, Liao R, Yu Y, Zhai H, Wang Y, Sack R, Peters AH, Chen J, Wu H, Huang Z, Hu M, Qi W, Lu C, Atadja P, Oyang C, Li E, Yi W, Zhou S.

Anal Chem. 2014 Oct 7;86(19):9679-86. doi: 10.1021/ac502333a. Epub 2014 Sep 8.

PMID:
25166916
8.

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors.

Bots M, Verbrugge I, Martin BP, Salmon JM, Ghisi M, Baker A, Stanley K, Shortt J, Ossenkoppele GJ, Zuber J, Rappaport AR, Atadja P, Lowe SW, Johnstone RW.

Blood. 2014 Feb 27;123(9):1341-52. doi: 10.1182/blood-2013-03-488114. Epub 2014 Jan 10.

9.

Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.

Cao F, Townsend EC, Karatas H, Xu J, Li L, Lee S, Liu L, Chen Y, Ouillette P, Zhu J, Hess JL, Atadja P, Lei M, Qin ZS, Malek S, Wang S, Dou Y.

Mol Cell. 2014 Jan 23;53(2):247-61. doi: 10.1016/j.molcel.2013.12.001. Epub 2014 Jan 2.

10.

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.

Matthews GM, Lefebure M, Doyle MA, Shortt J, Ellul J, Chesi M, Banks KM, Vidacs E, Faulkner D, Atadja P, Bergsagel PL, Johnstone RW.

Cell Death Dis. 2013 Sep 12;4:e798. doi: 10.1038/cddis.2013.306.

11.

NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.

Huang Z, Wu H, Chuai S, Xu F, Yan F, Englund N, Wang Z, Zhang H, Fang M, Wang Y, Gu J, Zhang M, Yang T, Zhao K, Yu Y, Dai J, Yi W, Zhou S, Li Q, Wu J, Liu J, Wu X, Chan H, Lu C, Atadja P, Li E, Wang Y, Hu M.

Cancer Res. 2013 Oct 15;73(20):6277-88. doi: 10.1158/0008-5472.CAN-13-1000. Epub 2013 Aug 26.

12.

The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.

Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, Lienlaf M, Atadja P, Seto E, Weber J, Sotomayor EM, Villagra A.

Melanoma Res. 2013 Oct;23(5):341-8. doi: 10.1097/CMR.0b013e328364c0ed.

13.

SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells.

Scuto A, Kirschbaum M, Buettner R, Kujawski M, Cermak JM, Atadja P, Jove R.

Cell Death Dis. 2013 May 16;4:e635. doi: 10.1038/cddis.2013.159.

14.

Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy.

Yang Y, Fiskus W, Yong B, Atadja P, Takahashi Y, Pandita TK, Wang HG, Bhalla KN.

Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6841-6. doi: 10.1073/pnas.1217692110. Epub 2013 Apr 8.

15.

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, Giles FJ, Scott JW, Parker K, Liu A, Woo M, Atadja P, Mishra KK, Ottmann OG.

Leukemia. 2013 Aug;27(8):1628-36. doi: 10.1038/leu.2013.38. Epub 2013 Feb 6.

PMID:
23385375
16.

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.

Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, Zeng J, Li M, Fan H, Lin Y, Gu J, Ardayfio O, Zhang JH, Yan X, Fang J, Mi Y, Zhang M, Zhou T, Feng G, Chen Z, Li G, Yang T, Zhao K, Liu X, Yu Z, Lu CX, Atadja P, Li E.

Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360-5. doi: 10.1073/pnas.1210371110. Epub 2012 Dec 10.

17.

Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.

Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A, Bhalla KN.

Oncotarget. 2012 Nov;3(11):1416-27.

18.

Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.

Fiskus W, Rao R, Balusu R, Ganguly S, Tao J, Sotomayor E, Mudunuru U, Smith JE, Hembruff SL, Atadja P, Marquez VE, Bhalla K.

Clin Cancer Res. 2012 Nov 15;18(22):6227-38. doi: 10.1158/1078-0432.CCR-12-0873. Epub 2012 Aug 29.

19.

ING1 and 5-azacytidine act synergistically to block breast cancer cell growth.

Thakur S, Feng X, Qiao Shi Z, Ganapathy A, Kumar Mishra M, Atadja P, Morris D, Riabowol K.

PLoS One. 2012;7(8):e43671. doi: 10.1371/journal.pone.0043671. Epub 2012 Aug 20.

20.

Analysis of pan-African Centres of excellence in health innovation highlights opportunities and challenges for local innovation and financing in the continent.

Nwaka S, Ochem A, Besson D, Ramirez B, Fakorede F, Botros S, Inyang U, Mgone C, Adae-Mensah I, Konde V, Nyasse B, Okole B, Guantai A, Loots G, Atadja P, Ndumbe P, Sanou I, Olesen O, Ridley R, Ilunga T.

BMC Int Health Hum Rights. 2012 Jul 27;12:11. doi: 10.1186/1472-698X-12-11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk